rtog 9802: the end of the beginning?
Post on 25-Feb-2016
206 Views
Preview:
DESCRIPTION
TRANSCRIPT
RTOG 9802: the end of the beginning?
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
Low grade glioma
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
What are the issues?
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
R9802 SCHEMA
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
Presented at ASCO 2008, published 2012
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
What were the issues?
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
ASCO 2014: Overall Survival
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
Conclusions
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
Three trials on adjuvant PCV chemotherapy: the anaplastic OD and LGG trials
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
Delayed benefit of chemotherapy
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
New WHO grading scheme?
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
What are the unanswered questions?
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
What are the unanswered questions?
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
What are the unanswered questions?
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
EORTC 22033 on RT vs TMZ in low grade glioma: PFS in relation to 1p status
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
Slide 16
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
2014: the role of chemotherapy established in all diffuse glioma
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
Now what?
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
Slide 19
Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting
top related